pre-IPO PHARMA

COMPANY OVERVIEW

Palladio Biosciences, Inc, a private biotech company, was founded in 2015 to develop transformative medicines for orphan diseases of the kidney.


LOCATION

  • Newtown, PA, USA

  • THERAPEUTIC AREAS

  • Kidney Disease
  • Rare Diseases

  • WEBSITE

    http://palladiobio.com/


    CAREER WEBSITE


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Nov 17, 2020

    Palladio Biosciences Announces First Patient Dosed With Lixivaptan in The ALERT Study, a Phase 3 Study of ADPKD Patients Previously Discontinued From Treatment With Tolvaptan Due to Liver Toxicity


    Oct 20, 2020

    Palladio Biosciences Announces Presentation of Data from a Study of Lixivaptan Use in an ADPKD Patient who Previously Experienced Liver Toxicity with Tolvaptan During the American Society of Nephrology Kidney Week 2020 Meeting


    Nov 5, 2019

    Palladio Biosciences Announces Presentations of ELiSA Phase 2 Study Results and Phase 3 Lixivaptan Clinical Program Design during the American Society of Nephrology Kidney Week 2019 Meeting


    Nov 5, 2019

    Palladio Biosciences Announces Presentations of ELiSA Phase 2 Study Results and Phase 3 Lixivaptan Clinical Program Design during the American Society of Nephrology Kidney Week 2019 Meeting


    Oct 11, 2019

    Palladio Biosciences Appoints Marella Thorell Chief Financial Officer


    For More Press Releases


    Google Analytics Alternative